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A regulatable fusion protein was constructed for controlling the localization of plasmid products. A ligand-inducible
nuclear localization signal, nuclear export signal (NES) and a truncated form of the ligand binding domain of the
progesterone receptor were attached to the desired protein. Enhanced green fluorescent protein (EGFP) was used as a model
protein and its trafficking between the nucleus and cytoplasm was studied using fluorescence microscopy in response to the
ligand, mifepristone. It was found that the protein trafficking into the nucleus was dose dependent with ligand concentration.
Increasing the ligand dose from 1 to 100 nM enhanced import and reduced the rate of export of the fusion protein from the
nucleus to the cytoplasm. This study demonstrates the feasibility of using an export signal and a ligand-inducible nuclear
import signal as a bi-directional on/off switch with potential use for controlled targeting of therapeutic proteins to subcellular
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Gene therapy has been cited as the future of human
medicine [1] and is a rapidly evolving field with
significant room for improvement. The development
of tailored, novel gene products will improve the
management of human diseases with the next era of
gene therapy witnessing a complete manipulation of
the delivered gene products in the targeted cells. The
bi-directional protein switch described in this paper
provides a step in this direction by allowing the
scientist to control the function of the therapeutic
gene product by changing its subcellular localization.
The major goal of the project is to greatly expand the
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modulating the protein transport and compartmental-
ization mechanisms. Delivery of gene therapy prod-
ucts to specific sites of action can be controlled by
removing the natural signals (import and export) of
the gene of interest and replacing them with regulat-
able signals. This allows gene therapy to be directed
by the health care practitioners rather than the endog-
enous gene. In the case of the endogenous gene,
regulation of localization may be dependent on factors
in the cell that are poorly defined, difficult to control,
or malfunctioning.
Eukaryotic cells are highly organized structures
that use compartmentalization to regulate biological
activity by defining locations of molecules, pathways
and processes [2]. Proteins and other vital molecules
have specific sites of localization and function in
subcellular compartments, enabling the cell to control
vital cellular processes and functions. Protein traffick-
ing between the nucleus and the cytoplasm occurs
mainly through nuclear pore complexes (NPCs) in the
nuclear envelope. These passive diffusion channels
have an effective diameter of 9 nm and allow for
passage of proteins of less than 45–60 kDa [3,4].
Transport of larger macromolecules occurs via amino
acid signals which are recognized by specific import
and export receptors [5].
Import receptors recognize and bind to certain
amino acid sequences called nuclear localization sig-
nals (NLS). Classical NLSs can be monopartite and
contain a single stretch of basic amino acids, like the
signal found in SV-40 large T-antigen (PKKKRKV)
[6]. Bipartite and tripartite nuclear localization signals
have also been identified in proteins like nucleoplas-
min and steroid hormone receptors [7,8]. Proteins
containing nuclear localization signals are imported
into the nucleus by importin a/h heterodimer. Impor-
tin a contains the NLS binding site while importin h
mediates the translocation through the nuclear pore
[5,9].
The classical export receptor CRM1 recognizes
and binds to leucine-rich nuclear export signals
(NESs) [10,11]. Classical NESs are typically 8–11
amino acid sequences with hydrophobic residues. A
common consensus NES is LX(1 – 3)LX(2 – 3)LXJ
(where L= Leu X= spacer J = Leu, Val or Ile) [12].
CRM1 also functions as an export receptor for RNA
[5]. A non-classical NES is recognized by calreticulin(CRT) a multifunctional calcium binding protein that
resides in the ER lumen. CRT has been shown to
recognize a KVFFKR amino acid motif in steroid
receptors, and may export steroid receptors such as
the glucocorticoid receptor under stress conditions
[13].
The selective movement of macromolecules across
the nuclear envelope can be exploited for novel drug
therapy by blocking or facilitating the localization of
the delivered protein to its active compartment via
signal sequences. This paper demonstrates the feasi-
bility of using ligand-inducible nuclear import and
export signals as a bi-directional on/off switch for
controlled targeting of proteins to the nucleus and
cytoplasm. The localization and rate of delivery of
these proteins can be manipulated by using naturally
occurring signal sequences that are regulated by an
external stimulus such as a ligand.
A protein capable of bi-directional trafficking was
constructed by tagging it with a strong NES, a ligand-
inducible NLS [8], and a mifepristone-specific ligand
binding domain (LBD) [14]. The protein chosen for
proof of concept was enhanced green fluorescent
protein (EGFP), which can easily be tracked in living
cells [15–17]. NESs with different strengths were
initially tested and optimized. In the ‘‘off’’ or unli-
ganded state, the controlled targeting system with the
protein of interest (EGFP) is directed to the cytoplasm
by virtue of its nuclear export signal (NES). The
targeting system is turned ‘‘on’’ when ligand is added.
This sends the protein to the nucleus due to the ligand-
inducible NLS and interaction with the LBD. The
system can be turned ‘‘off’’ again by removing the
ligand, resulting in the export of the protein back to
the cytoplasm. The protein can be cycled multiple
times as needed.
Trafficking was studied using fluorescence micros-
copy. A recent paper showed that fluorescence mi-
croscopy is a valid method of quantitation of
trafficking [18]. It was shown that, despite the het-
erogeneity of cells, trends and conclusions could be
derived from cellular microscopic data. Many groups
have used confocal/fluorescence microscopy for
studying and quantitating protein dynamics [19,20].
Live cell imaging with fluorescence microscopy
allows for the tracking of movement of the fusion
protein over time. Live cell imaging is a better method
for studying translocation as it can overcome any
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microscopy of fixed cells was performed as well and
showed protein localization trends similar to fluores-
cence microscopy (data not shown).2. Material and methods
2.1. Cell line
1471.1 cells (murine adenocarcinoma cells that do
not express endogenous progesterone receptor) were
used for these studies. 1471.1 cells were maintained in
Dulbecco’s modified eagle’s medium (DMEM;
GIBCO BRL, Grand Island, NY) with 10% FBS
(Hyclone Laboratories, Logan, UT), penicillin strep-
tomycin (100 U/ml, GIBCO BRL), gentamycin (0.5
mg/ml, Hyclone) and L-glutamine (2 mM, Hyclone) in
a 5% CO2 incubator at 37 jC.
2.2. Subcloning and construction of plasmids
PCR was performed on pEGFP-PRB [12] to ex-
tract out the 246 amino acid ligand binding domain
(LBD) fragment (645–891) using the primers 5V-
GGTACCGTCAGAGTTGTGAGAGCACTGGA-3V
and 5V-GGATCCCAAGAGTACAGATGAAGT-
TGTTTG-3V with KpnI and BamHI sticky ends. This
fragment was inserted into the multiple cloning site of
EGFP-C1 (BD Biosciences Clontech, Palo Alto, CA;
encodes enhanced green fluorescent protein and con-
tains the CMV promoter/enhancer) digested with the
enzymes KpnI and BamHI to create the plasmid
EGFP-LBD. PCR was performed on pEGFP-PRB to
obtain the 43 amino acid inducible nuclear loca-
lization signal (NLSi) using the primers: 5V-AATT-
CTGCAATGGAAGGGCAGCAGCACA-3V and 5V-
GTCGACTCGACCTCCAAGG ACCATGCC-3V
with restriction sites for the enzymes EcoRI and SalI.
The plasmid EGFP-LBD was then digested with
EcoRI and SalI and ligated to the insert NLSi to make
pEGFP-NLSi-LBD.
EGFP-15 Pep-NLSi-LBD (which contains the 15




strand encoding for the 15 amino acid peptide in the PRDNAbinding domain into the vector EGFP-NLS-LBD,
which had been digested with BspEI and XhoI.
EGFP-MAPKK-NLSi-LBD was subcloned by
inserting the oligonucleotide 5V-CCGGACTTCA-
AAAAAAACTTGAAGAACT TGAACTTGACG-
GTTC-3V and its complementary strand encoding the
strong nuclear export signal protein from MAPKK
into the construct EGFP-NLSi-LBD digested with
BspEI and XhoI.
EGFP-NES-NLSi-LBD was subcloned by inserting
the cDNA encoding the PRNES (KVFFKR), which
has cohesive ends to enzymes BspE1 and XhoI and
ligated to EGFP-NLS-LBD cut with BspE1 and XhoI.
EGFP-DBD-NLSi-LBD was constructed by per-
forming PCR on EGFP-PRB to extract the 63 amino
acid fragment encoding for the DNA binding domain
of PRB with BspE1 and XhoI restriction sites and
was ligated to EGFP-NLS-LBD cut with BspE1 and
XhoI.
EGFP-HIV-NLSi-LBD was subcloned by inserting
the oligomers encoding the HIVNES 5V-CCGGACTT-
CAACTTCCTCCTCTTGAGAGACTTACTCTTTC-
3V and complementary strand: 5V-TCGAGAAAGAG-
TAAGTCTCTCAAGAGGAGGAAGTTGAAGT-3V
into EGFP-NLS-LBD cut with BspE1 and XhoI.
EGFP-Adeno-NLSi-LBD was subcloned using pri-
mers 5V-CCGGACTTTATCCTGAGAGAC TTA-
GAAGAATTCTTACTTC-3V and its complementary
strand 5V-TCGAGAAGTAAGAAT TCTTCTAAGT-
CTCTCAGGATAAAGT-3V and ligated to EGFP-
NLS-LBD cut with BspEI and XhoI.
EGFP-p53-NLSi-LBD was constructed similarly
using 5V-CCGGAATGTTTA GAGAGCTTAAT-
GAGGCTCTTGAGCTTAAATC-3V and the comple-
men t a ry s t r and 5V-TCGAGATTTAAGCT-
CAAGAGCCTCATTAAGCTCTCTAAACAT-T-3V.
EGFP-PRB NES2-NLSi-LBD was constructed by




EGFP-NLSi-LBD cut with BspEI and XhoI.
2.3. Transient transfections
Transient transfections of 1471.1 cells were carried
out by electroporation as previously described [12].
Briefly, 5 106 cells were transfected with 2 Ag of
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DNA, pGL3 basic (Promega, Madison, WI), to make
10 Ag total DNA. Transfections were performed using
an Electrosquare porator ECM 830 Electroporation
system (BTX, San Diego, CA) at a voltage of 140 V
for 10 ms with three pulses in a total of 100-Al cold
plain DMEM. After a 5–10-min recovery on ice, the
electroporated cells were diluted with complete phe-
nol red-free DMEM (10% FBS charcoal/dextran
treated, Hyclone, L-glutamine, pen-strep and genta-
mycin) and plated on a clear coverglass (Corning no.
1, 22 mm2) in six well plates or into live cell chambers
(Lab-tek chamber slide system, 2 ml, Nalge NUNC
International, Naperville, IL). These cells were then
incubated in a 5% CO2 incubator at 37 jC for 18–24 h.
2.4. Microscopy
Approximately 24 h after electroporation, protein
expression of NES-NLSi-LBD plasmids was viewed
by fluorescence microscopy in fixed or living cells.
An Olympus IX701F inverted fluorescence micro-
scope (Scientific Instrument Co, Aurora, CO) with
high-quantity narrow band GFP filter (excitation filter
set HQ480/20; emission filter set HQ510/20 nm; with
beamsplitter Q4951p) from Chroma Technology
(Brattleboro, VT) was utilized. Cells were photo-
graphed at a magnification of 60 using an F-View
Monochrome CCD camera. To minimize photo-
bleaching of the EGFP chromophore, cells were
imaged using neutral-density filters that transmit
25% of the total light, and short exposure times of
500 ms were used.
In addition, a Zeiss (Thornwood, NY) LSM 510
confocal imaging system with an Axioplan 2 micro-
scope (100 plan-apo objective, NA= 1.4, oil) and an
argon laser was used for imaging fixed cells. A laser
line with excitation of 488-nm and a 505-nm-long-pass
emission filter was used. For fixed cell microscopy, the
coverslips were rinsed with PBS, incubated with 4%
paraformaldehyde for 20 min, sealed with clear nail
polish and inverted onto microscope slides.
For live cell imaging a Nevtek ASI 400 Air Stream
Incubator (Burnsville, VA) with variable temperature
control was used to maintain the microscope stage and
the live cell chambers at 37 jC. Cells were photo-
graphed using a F-View Monochrome CCD camera
on an IX701F microscope (mentioned above) at timepoints 0, 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120
min for import studies of the various constructs.
Export studies were conducted over a period of 24
h using the same conditions.
2.5. Ligand induction and removal studies
Cells transfected with a protein switch plasmid
were induced with ligand 24 h post transfection.
Mifepristone in final concentrations of 1, 10 and
100 nM were used for induction of import. Prior to
microscopy, transfected cells were either fixed with
4% paraformaldehyde or plated in live cell chambers.
For removal of ligand, cells were washed five times
with PBS, rinsed with DMEM plain media and then
fresh media was added. Cells were fixed for the
primary studies to test the feasibility of the system
using confocal microscopy. These results were then
corroborated using live cell fluorescence microscopy
to avoid any potential artifacts due to fixation.
2.6. Preliminary studies using fixed cells
To determine if the protein construct was capable
of undergoing regulated import and export, experi-
ments were performed on fixed cells. Two milliliters
of transfected cells were plated on glass coverslips in
four 6 well plates. Cells in the first plate were fixed
after a 24-h incubation period to be used as a control
(off state). Cells in plates 2, 3 and 4 were induced with
10 nM MFP. 2 h after incubation, cells in plate 2 were
fixed with 4% paraformaldehyde and examined for
import of fusion protein. Wells in plates 3 and 4 were
washed five times with phosphate buffer saline (Medi-
atech, Herndon, VA) and then rinsed and incubated
with phenol red-free media. After an 8-h incubation,
cells in plate 3 were fixed with paraformaldehyde and
examined for export of the fusion protein. If the
protein was capable of import, on ligand induction,
and export on ligand removal, cells in plate 4 were re-
induced for two h with 10 nM MFP. Constructs that
were capable of bidirectional trafficking were chosen
for live cell import and export studies.
2.7. Import studies on living cells
Time lapse studies on live cells were carried out to
test the kinetics of import with increasing ligand con-
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and 3 ml of fresh media was added. Cells were kept in
the incubator for 30 min after which ligand was added
in the concentration of 1, 10 or 100 nM. Import studies
were performed over a time period of 2 h.
2.8. Export studies on living cells
Export studies after hormone washout were carried
out in live cells. These studies were performed to
determine if the export rate of fusion proteins was
dependent on MFP induction doses. One milliliter of
electroporated cells was plated in live cell chambers
with 2 ml of phenol red-free DMEM. Twenty-four
hours later, media was removed and 2 ml of fresh
media was added. Cells were kept in the incubator for
30 min and ligand was added to make the final
concentration 1 or 10 nM. After incubating for 2 h,
the ligand was removed by washing five times with
PBSwithout calcium ormagnesium followed by a rinse
with phenol red-free DMEM. Two milliliters of fresh
complete phenol red-free DMEM was then added and
the chamber was kept in the incubator at 37 jC for the
desired periods. The export was studied by detecting
GFP fluorescence under the microscope at time points
of 8, 12 and 24 h after ligand withdrawal and washing.
2.9. Quantitation of EGFP fluorescence in the
nucleus and cytoplasm
The amount of fluorescence in the nuclear and
cytoplasmic compartments was quantitated as previ-
ously described [18]. All images were analyzed by
analySISR software (Soft Imaging System, Lake-
wood). This software allows one to trace an outline
around a region of interest (ROI), then the pixel
(fluorescence) intensity in that ROI is calculated. After
tracing, the intensities were calculated in the total cell
area (total intensity) and in the nucleus (nuclear inten-
sity). Cytoplasmic fluorescence was calculated by
subtracting the nuclear intensity from the total intensi-
ty. The fluorescence measurements were then normal-
ized to area by calculating the average nuclear and
cytoplasmic intensities. These average values were
obtained by dividing the intensities by the area of the
nucleus and cytoplasm, respectively (Eq. (1) and (2)).
Calculating the average intensity overcomes variations
due to differences in the shape and spread of the cells.To calculate the relative intensity of the nucleus to the
cytoplasm, the average nuclear intensity (nuclear in-
tensity divided by nuclear area) was calculated for each
cell, and divided by the average cytoplasmic intensity
(intensity per area), and normalized to the first relative
intensity value (before induction with ligand) (Eq. (3)
and (4)). This denotes the actual difference in the
fluorescence intensity due to import of the fluorescent














where, N.I. = nuclear intensity; N.A. = nuclear area;
T.I. = total fluorescence intensity; T.A. = total area of
the cell; C.I. = cytoplasmic intensity; Rel.I.T0 = Rela-
tive intensity measured either at time T0 (before ligand
induction) or at the time T (after ligand induction);
Rel.I.Tn = Relative intensity measured at time Tnminus
relative intensity at T0 to analyze the actual increase in
relative fluorescence after ligand induction.
2.10. Statistical analysis
The results of import and export studies of
MAPKK and HIV NES constructs carried out in
living cells were analyzed quantitatively. For all
experiments, 10 cells were chosen for analysis
(n = 10). The relationship between time and nuclear
intensity for each dose tested was fitted to a two
parameter exponential relationship using nonlinear
regression (Sigma Plot, Chicago, IL). The model
parameters were the maximum relative cellular fluo-
rescence intensity and a rate constant that defined the
time until transport reached steady state. Differences
in the rate constant as a function of ligand concentra-
tion were assessed using Kruskal–Wallis ANOVA
and Student–Newman–Kuels test to isolate individ-
Table 1




Export signal seq Strength Rate of
export
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was used to determine differences in export over time
with the Student–Newman–Kuels test to isolate in-
dividual differences. For either test, a p value < 0.05
was considered significant. (speed)























PRB NES2 LHDLVKQLHL n/a n/a3. Results
3.1. The initial localization of the construct depends
on the strength of the NES
As shown in Figs. 1 and 2, protein switch constructs
showed variable degrees of localization in the cyto-
plasm during the protein switch off state. In the off
state, the protein should localize in the cytoplasm
(inactive compartment). This is achieved by including
a strong NES in the protein construct. NESs recognized
either by CRM1 or CRT were tested (Table 1). The
classical NESs that function via the CRM1-mediated
export pathway have been classified according to their
strength and rate of export [22,23] (Table 1); however,
KVFFKR containing motifs are recognized by the non-
classical exporter calreticulin (CRT). The relative
strength of the NESs recognized by calreticulin versus
the classical nuclear export signals is not yet known.
MAPKK-NLSi-LBD (Fig. 2a), Pep-NLSi-LBD
(Fig. 1b), HIV-NLSi-LBD (Fig. 2b) and PRB NES2-
NLSi-LBD (Fig. 2c) mainly localized in the cyto-
plasm, prior to addition of ligand. Proteins with other
weaker NESs like the export signal from adenovirus
(Fig. 2d), p53 (Fig. 2e), DNA binding domain of PRB
(Fig. 1a) and a minimal putative NES (KVFFKR) of
PRB, recognized by calreticulin (Fig. 1c) did not
cause predominant cytoplasmic localization of the
EGFP protein. MAPKK, being the strongest nuclearFig. 1. Constructs with non-classical NES (KVexport signal used in these studies caused complete
cytoplasmic localization of the fusion protein. Protein
constructs with HIV NES and PRB NES were more
cytoplasmic compared to the Pep-NES. In summary,
stronger nuclear export signals directed the protein to
be more localized in the cytoplasm in the unliganded
or off state.
3.2. Constructs are capable of subcellular trafficking
As shown in Fig. 3, the constructs that localized
mainly in the cytoplasm in the off state were studied
for shuttling capacity. Plasmids containing MAPKK
NES (Fig. 3A), HIV NES (Fig. 3B), 15 amino acid
peptide (Fig. 3C) with the KVFFKR motif present in
the DNA binding domain of progesterone receptor,FFKR) motif recognized by calreticulin.
Fig. 2. Constructs with classical NESs recognized by CRM1, from strongest to weakest.
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[12] were tested for nuclear import by inducing with a
dose of 10 nM MFP. The off state was re-introduced
by washing off ligand. The protein translocated back
into the cytoplasm within 8 h of ligand removal.
Reinduction with the ligand caused protein import
into the nucleus. This shows that the localization of
the chimeric protein with the import and export
signals can be regulated via the ligand. The amount
of protein localized in the nucleus on induction also
depended on the strength of the NES. If the NES was
too strong the import into the nucleus was lower. The
construct with MAPKK NES showed more cytoplas-
mic localization in the uninduced state compared to
the constructs containing HIV NES/Pep NES or PRB
NES 2. All the four constructs showed that the fusion
protein could be switched on or off via nucleocyto-
plasmic trafficking.
3.3. Nuclear localization of the fusion protein can
only be directed by mifepristone (MFP)
The LBD attached to the protein switch construct
has been shown to be specific to low concentrations of
mifepristone in earlier studies [24]. The LBD used in
these constructs is a 42 amino acid truncated versionof the LBD from wt PRB, (amino acids 645–891). It
was important to determine whether the protein switch
constructs were truly non-responsive to natural pro-
gesterone and synthetic progestin (R5020). The
effects of progesterone (Fig. 4A) and R5020 (Fig.
4B) in doses as high as 1000 nM were studied, and
was found that neither drug could mediate the nuclear
localization of these constructs. Normally, doses of
R5020 or progesterone of 100 nM or higher can cause
nuclear localization of wt PRB in as little as 30 min
[21]. Therefore, both endogenous progesterone and a
synthetic progestin such as R5020 do not have any
effect on the import of the protein construct. One
possible concern with MFP is that it can antagonize
the inherent progesterone and glucocorticoid receptors
found in mammalian cells. However, the concentra-
tion of MFP required for this antagonism is in the
micromolar range [25,26]. Therefore, the nanomolar
concentrations of MFP required for the protein switch
will not cause any general endogenous antagonism.
3.4. Dependence of import characteristics on ligand
concentration
Using live cell microscopy, pictures of nuclear
localization of the fusion protein containing EGFP
Fig. 3. Off–on–off–on cycles of induction of constructs into the nucleus. Initially, no ligand is present (a). With the addition of ligand (b) the
constructs translocate to the nucleus. The removal of ligand (c) results in translocation back to the cytoplasm within 8 h, and addition of ligand
(d) causes translocation back to the nucleus.
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Fig. 4. MAPKK NES construct was tested for its response to progesterone and synthetic progestin R5020, by induction with 100 and 1000 nM
of each for 2 h and studying import.
Fig. 5. Representative time dependent import and export studies of HIV NES constructs induced with 10 nM MFP. Only a few time points of the
time lapse experiments are shown. Maximum relative import was achieved as early as 40 min after ligand induction. Export of most of this
protein occurred after 8 h of ligand withdrawal (LW= ligand withdrawal).
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Fig. 6. Import of MAPKK and HIV NES constructs with 1, 10, and 100 nM MFP. Import of the two proteins induced with 10, 100 or 1000 nM
was studied for 2 h. Data is reported as meanF S.D., n= 10. A p< 0.05 was obtained for the difference in rates between MAPKK NES induced
with doses of 1 and 100 nM. A statistically significant difference (p< 0.05) was obtained for all the three doses tested for HIV NES (L= ligand,
LW= ligand withdrawal).
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40, 50, 60, 90, and 120 min to determine the kinetics
of nuclear localization of constructs with MAPKK
and HIVexport signals. The import was studied over a
period of 2 h, since after 2 h no further increases in
import were seen (data not shown). The effects of
MFP in doses of 1, 10, and 100 nM were studied and
a representative example of 10 nM is shown in Fig.
5A. Relative intensity in the nucleus was plotted as a
function of time for doses of 1, 10, and 100 nM MFP
for the MAPKK and HIV NES constructs (Fig. 6A
and B). The maximum relative intensities for the
MAPKK NES construct were 0.11 at 1 nM, 0.24 at
10 nM, and 0.27 at a dose of 100 nM MFP. Maximum
relative intensities for the HIV NES construct were
0.20 at 1 nM, 0.31 at 10 nM, and 0.38 at a dose of 100
nM of MFP, which were higher than the MAPKK
constructs indicating that import is slower for a
protein with a stronger NES.Fig. 7. Live cell export studies were conducted for MAPKK NES and for co
proteins was studied over a period of 24 h. Data is reported as meanF S.D
export between 8, 12 and 24 h time points (L= ligand, LW= ligand withdThe rate of nuclear import for both MAPPK NES
and HIV NES constructs was MFP dose dependant.
This was indicated by the steepness of the import
curves for 1, 10 and a 100 nM in Fig. 6A and B. The
amount of protein entering the nucleus was also dose-
dependent as shown by the increase in maximum
relative intensity on induction with 1 and 100 nM
MFP. The import rate constants for MAPKK con-
structs were 0.139F 0.0140, 0.107F 0.00765,
0.421F 0.267 for the three doses, respectively. There
was a significant difference in the rate constants for
the higher doses ( p < 0.05, Kruskal–Wallis test with
SNK correction for multiple comparison). The con-
structs containing the HIV NES also showed a sig-
nificant difference in import rate constant. These
import rates were 0.0547F 0.00138, 0.226F
0.00815 and 0.609F 0.129 for the three doses, re-
spectively, which were all significantly different
( p < 0.05, Kruskal–Wallis test with SNK correctionnstruct HIV NES induced with MFP 1 and 10 nM. Export of the two
., n= 10. No statistical difference (p>0.05) was found for the rate of
rawal).
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MAPKK NES, showed an effect at the higher doses as
the import rate constant with the dose of 100 nM was
higher than that of 10 and 1 nM, but there was no
significant difference found between the doses of 10
and 1 nM. Results also indicated that there was a 9-
fold increase in the rate constant between the doses of
100 nM and 1 nM for HIV, while the MAPKK fusion
proteins showed an 8-fold increase between the two
doses. Thus, the strength of the NES played a role in
determining the balance between the nuclear import
brought about by the NLS and the inherent cytoplas-
mic localization due to the NES.
3.5. Dose of the ligand and time dependence of
protein localization to the cytoplasm after washing
After inducing the cells for 2 h with MFP at a
concentration of 1 or 10 nM, the export of MAPKK
NES and HIV NES constructs were studied using live
cell microscopy. Export was observed at time points
of 8, 16 and 24 h (Fig. 7A and B) after hormone
washout. Friedman repeated measures ANOVA was
used to determine differences in export over time.
While there was a significant change in export at the
8-h time point after washout (p < 0.05), it was found
that there were no significant differences in the
cytoplasmic localization of the construct, between
the 8-, 12-, and 24-h time points (p>0.05, Friedman
ANOVA). Thus, export is essentially complete by 8 h.
These results demonstrate that high concentrations of
the ligand lead to reduction in the rate of export of the
protein. This study was carried out for only for 1 and
10 nM as these might be more relevant for clinical
applications as compared to higher doses [25,26].4. Discussion
This paper demonstrates the feasibility of bi-direc-
tional trafficking of a model protein. The constructs
described here contain a nuclear export signal to cause
the cytoplasmic localization of the protein in the off
state, a nuclear import signal (NLSi) that is responsive
to ligand induction and a ligand binding domain
(LBD) that confers responsiveness to MFP in the on
state. The removal of the ligand results in the cyto-
plasmic or off state of the protein. The NES-NLSi-LBD plasmid is transcribed into mRNA and translated
into protein in the cytoplasm. In the absence of MFP,
the export signal in the protein dominates and results
in the cytoplasmic localization due to interaction with
the export receptors (CRM1 or CRT). Induction with
MFP causes the ligand binding domain and the
ligand-inducible nuclear localization signals to take
over. This results in a conformational change in the
protein that allows it to translocate to the nucleus via
the nuclear import machinery involving nuclear im-
port receptors. Removal of ligand triggers protein
export to the cytoplasm via its export receptor.
There have been reports of other systems that are
capable of inducing gene expression of plasmids. In
these cases, the inducing agent binds to response
elements on DNA to promote gene expression. The
inducing agents include heavy metal ions, heat shock,
isopropyl beta D-thiogalactoside (h Gal) and steroid
hormones [27–29]. Other inducible systems include
those controlled by antibiotics like tetracycline [30–
32], novobiocin [33], rapamycin [34]. Ecdysone re-
ceptor-based gene regulation system has also been
described [35,36]. Other types of induction systems
have also been described [37,38].
Recently in a review by Lee and Hannick [39], it
was mentioned that the ‘‘ability to sequester a protein
or transcription factor in the cytoplasm, to allow its
transport into the nucleus in response to specific
stimuli, and then to remove it from the nucleus once
the stimulus is removed, provides a powerful mech-
anism for the temporal regulation of gene expression’’
Similarly, the ability to change the subcellular local-
ization of a therapeutic protein from a compartment
where the protein is active to one where it becomes
inactive has potential use in this era when gene
therapy is at the brink of becoming a major player
in therapeutics.
Researchers in the past have exploited signal
sequences for unidirectional targeted delivery of
genes or gene therapy products (proteins) [40].
However, specific, bidirectional control of proteins
is the next phase in gene therapy. Optimally, bi-
directional targeting of gene products would direct
these proteins in a controlled manner by use of an
external stimulus to a specific subcellular compart-
ment where they are exclusively active, and removed
from the compartment when the stimulus is removed.
A regulatable fusion protein with the activation
C. Kanwal et al. / Journal of Controlled Release 98 (2004) 379–393 391domain of a steroid receptor co-repressor, NCoR, is
currently being constructed. This can be used for
controlled transcriptional repression of progesterone
receptor B depending on its subcellular localization.
On localization in the nucleus, it can repress proges-
terone-mediated gene transcription and removal from
the nucleus on ligand withdrawal can abolish the
repression.
There are many proteins in a cell whose functions
are directed by means of regulated traffic between the
active and inactive compartment. For example, steroid
hormone receptors and many other transcription fac-
tors only exert their genomic effects when directed to
the nucleus of cells. Once in the nucleus, these
receptors can interact with chromatin and the tran-
scription machinery, ultimately resulting in gene acti-
vation [41]. Localization controllable versions of
proteins via a protein switch could be used to correct
for mislocalization of endogenous proteins. For ex-
ample in chronic myeloid leukemia and Philadelphia
chromosome positive acute lymphoblastic leukemia,
BCR-ABL proteins are expressed. BCR-ABL proteins
have tyrosine kinase activity that leads to oncogenesis
[27,42]. BCR-ABL proteins are oncogenic in the
cytoplasmic compartment only, and must multimerize
in order to be active. Introduction of ligand regulat-
able mutant versions of BCR-ABL for gene therapy
should allow the clinician to direct the wild-type
BCR-ABL proteins to the nucleus, resulting in loss
of oncogenic activity. The use of the protein switch in
this situation is the focus of future studies.
Other tumor suppressors that mislocalize to the
cytoplasm in cancer cells include p53 and INI1 [43].
Similarly, the mislocalization of cell cycle inhibitors
can be detrimental. Relocalization of a cell cycle
inhibitor to the ‘‘wrong’’ compartment can lead to
tumor progression. This occurs with the cell cycle
inhibitor p21WAF-1 which, normally localizes in the
nucleus where it exerts its inhibitory action. Misloc-
alization to the cytoplasm leads to tumor progression
[44]. In addition to applications in cancer, controlled
delivery of gene therapy products will be useful in
chronic disease states that exhibit transient symptoms.
The protein switch described here can also function
as a safety switch to control gene therapy with the
inactive state being the default mechanism. The gene
is introduced via gene therapy, but becomes active
only when external ligand is added. At the first sign ofnegative side effects, gene therapy can be easily
terminated by removing the protein from the active
compartment. Another use of the protein switch is to
reduce side effects due to long-term exposure of
therapeutic agent when the protein is not continually
activated. Pulsatile delivery of gene therapy products
to the nucleus could reduce toxicity (analogous to
intermittent dosing of highly toxic cancer chemother-
apeutic agents). Chronic activation of target genes by
the therapeutic gene product has the potential to
activate other signal transduction pathways which
may lead to detrimental results. Similarly, if chronic
activation of the target gene triggered by the thera-
peutic agent is avoided, the likelihood of tolerance
decreases.
Thus, the protein switch has numerous applications
in the field of gene therapy where the control of the
gene therapy product is beneficial in maintaining the
safety and efficacy of the therapeutic gene.5. Conclusions
A protein switch responsive to nanomolar doses of
mifepristone (MFP) was created. This regulatable
fusion protein was tagged with nuclear localization
and export signals that caused the translocation of the
protein between the active and inactive compartment
in response to ligand induction. EGFP was used as a
model protein for bi-directional trafficking. Stronger
nuclear export signals tagged to EGFP caused pre-
dominant cytoplasmic localization as seen in Fig. 2a–
c. Induction and removal of MFP caused on/off cycles
of the MAKK NES, HIV NES, Pep NES and PRB
NES2 protein constructs shown in Fig. 3A–D. These
protein constructs were unresponsive to high doses of
progesterone and synthetic progestin (R5020) and
could only be induced with MFP (Fig. 4). Import
rates and amounts of protein in the nucleus were
dependant on MFP dose. Nuclear import occurred
within 20–120 min depending on the dose of MFP
used. Export of most of the protein into the cytoplasm
occurred within a period of 8 h. Thus, a fusion protein
capable of controlled trafficking between the active
and inactive compartment that will be useful in
regulatable gene therapy was constructed. In summa-
ry, the protein switch described here will allow for a
higher level of regulation of gene therapy products by
C. Kanwal et al. / Journal of Controlled Release 98 (2004) 379–393392exploiting and harnessing known import and export
signals for use in drug delivery.References
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